In stark contrast to the development of immunotherapies that block IL-1ꞵ in cancer treatment, many cancer immunotherapies are being designed that promote IL-18 signaling due to its beneficial antitumor effects [118,126,127,148]. This evidence concerns the gene IL1A and cancer.